SCHEMBL21293583

SCHEMBL21293583

CCOC(=O)CSC1COC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
ALDH1A1 P00352 6/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TRPA1 O75762 1/20 0.38
TSHR P16473 2/20 0.37
POLB P06746 2/20 0.37
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31631313 0.82 MGAM (0.44) MGAMGAASIMGAM2ALDH1A1
SCHEMBL21798381 0.82 LMNA (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL21798099 0.79 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL3703287 0.79 KMT2A (0.42) MGAMGAASIMGAM2ALDH1A1
SCHEMBL17785167 0.78 ALDH1A1 (0.42) MGAMGAASIMGAM2ALDH1A1
SCHEMBL21098110 0.76 MGAM (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL21798268 0.75 ALDH1A1 (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL16416318 0.74 MGAM (0.36) MGAMGAASIMGAM2ALDH1A1
SCHEMBL12818021 0.71 MGAM (0.44) MGAMGAASIMGAM2ALDH1A1
SCHEMBL6335294 0.69 ALOX15 (0.39) MGAMGAASIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 US disclosed
EP-4479388-A1 ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS Gilead Sciences, Inc. (US) 2024-12-25 EP disclosed
WO-2023154905-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-08-17 WO disclosed
US-11008312-B2 Pyridazine derivatives as RORc modulators GENENTECH, INC. (US) 2021-05-18 US disclosed
EP-3535255-A1 PYRIDAZINE DERIVATIVES AS RORC MODULATORS H. Hoffnabb-La Roche Ag (CH) 2019-09-11 EP disclosed
US-20190263794-A1 PYRIDAZINE DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, CCR1, CCR6 MGAM 4438/4885GAA 3120/4885SI 3768/4885
US-11008312-B2 Pyridazine derivatives as RORc modulators RORC, RORB, RORA MGAM 4730/4885GAA 4667/4885SI 4812/4885
US-20190263794-A1 PYRIDAZINE DERIVATIVES AS RORc MODULATORS RORC, RORB, RORA MGAM 4730/4885GAA 4667/4885SI 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.